Paliperidone palmitate, marketed as Invega Sustenna and Invega Trinza, is not yet available in generic form in the U.S. as of 2024 [1]. The U.S. Food and Drug Administration (FDA) has not approved any generic versions of these long-acting injectable antipsychotics [1].
When Might Generic Paliperidone Palmitate Become Available?
The availability of generic paliperidone palmitate hinges on the expiration of patents and any associated exclusivities protecting the branded products [2]. DrugPatentWatch.com tracks these patent expiries and potential launch dates for generics [2]. Specific dates for generic availability are often subject to ongoing litigation and regulatory reviews, making precise timelines difficult to predict [2].
What Are the Key Patents for Invega Sustenna and Trinza?
The primary patents covering paliperidone palmitate formulations and their use are held by Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals [3][4]. These patents address aspects of the drug's composition, manufacturing processes, and extended-release mechanisms [3][4]. Challenges to these patents by generic manufacturers are common and can impact the timeline for generic entry [2].
Who Else is Developing Generic Paliperidone Palmitate?
Several pharmaceutical companies are actively pursuing the development and approval of generic versions of paliperidone palmitate [2]. Companies like Teva Pharmaceuticals, Mylan, and Accord Healthcare have been noted in legal filings and patent landscape analyses as interested parties [2][3]. The status of their applications and any patent litigation directly influences when generic competition might emerge.
What Are the Current Treatment Options for Patients?
Currently, patients in the U.S. rely on branded paliperidone palmitate injections, Invega Sustenna (monthly) and Invega Trinza (quarterly), for long-acting treatment of schizophrenia and schizoaffective disorder [1]. These formulations are designed for intramuscular injection and are administered by healthcare professionals [1].
Why Might Generic Versions Be Delayed?
Generic drug development for complex formulations like long-acting injectables can face significant hurdles. These include replicating the specific pharmacokinetic profiles and ensuring bioequivalence to the reference product [5]. Patent litigation, which often arises when generic companies challenge existing patents, can also delay market entry for extended periods [2].
What Are the Potential Benefits of Generic Paliperidone Palmitate?
The introduction of generic paliperidone palmitate would likely lead to significant cost savings for patients and the healthcare system [5]. Generic drugs typically enter the market at a substantially lower price point than their branded counterparts, increasing accessibility and affordability [5].